Literature DB >> 19812578

Shifting paradigms: the seeds of oncogene addiction.

Charles L Sawyers1.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19812578     DOI： 10.1038/nm1009-1158

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  15 in total

1.  Chromosome studies on normal and leukemic human leukocytes.

Authors:  P C NOWELL; D A HUNGERFORD
Journal:  J Natl Cancer Inst       Date:  1960-07       Impact factor: 13.506

2.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors:  E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

3.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

Authors:  J M Goldman; R P Gale; M M Horowitz; J C Biggs; R E Champlin; E Gluckman; R G Hoffmann; S J Jacobsen; A M Marmont; P B McGlave
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

4.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

5.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

6.  Overriding imatinib resistance with a novel ABL kinase inhibitor.

Authors:  Neil P Shah; Chris Tran; Francis Y Lee; Ping Chen; Derek Norris; Charles L Sawyers
Journal:  Science       Date:  2004-07-16       Impact factor: 47.728

7.  Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome.

Authors:  A M Mes-Masson; J McLaughlin; G Q Daley; M Paskind; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

8.  Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.

Authors:  J B Konopka; S M Watanabe; J W Singer; S J Collins; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

9.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia.

Authors:  A de Klein; A G van Kessel; G Grosveld; C R Bartram; A Hagemeijer; D Bootsma; N K Spurr; N Heisterkamp; J Groffen; J R Stephenson
Journal:  Nature       Date:  1982-12-23       Impact factor: 49.962

10.  Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

Authors:  Neil P Shah; Brian J Skaggs; Susan Branford; Timothy P Hughes; John M Nicoll; Ronald L Paquette; Charles L Sawyers
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808
View more
  38 in total

1.  Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.

Authors:  Brian J Park; Zakary L Whichard; Seth J Corey
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

Review 2.  Will kinase inhibitors make it as glioblastoma drugs?

Authors:  Ingo K Mellinghoff; Nikolaus Schultz; Paul S Mischel; Timothy F Cloughesy
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

3.  Profile of Charles L. Sawyers.

Authors:  Prashant Nair
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-31       Impact factor: 11.205

4.  Resistance, epigenetics and the cancer ecosystem.

Authors:  Stephen B Baylin
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

Review 5.  Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics.

Authors:  Jonathan L Messerschmidt; Prianka Bhattacharya; Gerald L Messerschmidt
Journal:  Curr Oncol Rep       Date:  2017-08-12       Impact factor: 5.075

6.  A mouse transgenic approach to induce β-catenin signaling in a temporally controlled manner.

Authors:  Atish Mukherjee; Selma M Soyal; Jie Li; Yan Ying; Maria M Szwarc; Bin He; Ramakrishna Kommagani; Myles C Hodgson; Minoti Hiremath; Pamela Cowin; John P Lydon
Journal:  Transgenic Res       Date:  2010-12-02       Impact factor: 2.788

7.  Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.

Authors:  Yanli Jin; Jingfeng Zhou; Fang Xu; Bei Jin; Lijing Cui; Yun Wang; Xin Du; Juan Li; Peng Li; Ruibao Ren; Jingxuan Pan
Journal:  J Clin Invest       Date:  2016-09-19       Impact factor: 14.808

Review 8.  The current state of the art of quantitative phosphoproteomics and its applications to diabetes research.

Authors:  Chi Yuet X'avia Chan; Marina A Gritsenko; Richard D Smith; Wei-Jun Qian
Journal:  Expert Rev Proteomics       Date:  2016       Impact factor: 3.940

9.  Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.

Authors:  Zhongzheng Lu; Yanli Jin; Chun Chen; Juan Li; Qi Cao; Jingxuan Pan
Journal:  Mol Cancer       Date:  2010-05-19       Impact factor: 27.401

Review 10.  The hallmarks of premalignant conditions: a molecular basis for cancer prevention.

Authors:  Bríd M Ryan; Jessica M Faupel-Badger
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.